Colgate-PalmoliveKimberly-Clark
Live Report · Updated 29 July 2026

Colgate-Palmolive vs Kimberly-Clark

Global oral care and household products leader vs Global maker of tissue and personal care products. Which is the better buy for your portfolio in July 2026? Plain-English answer below.

Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, ...

Why It’s Moving

Colgate-Palmolive

CL faces downside pressure as analysts flag limited upside and valuation risk.

  • No major company-specific news, earnings release, or macro catalyst appears in the last 7 days, so the move is being driven mainly by analyst caution rather than a fresh event.
  • The bearish case centers on valuation: CL is trading close to its recent range while some broker forecasts still imply downside, signaling that expectations may already be stretched.
  • The stock’s defensive consumer-staples profile is helping limit volatility, but the lack of a near-term catalyst means investors are focusing on slower growth and limited re-rating potential.
Sentiment:
🐻Bearish
Kimberly-Clark

KMB’s upside case hinges on whether cost cuts can outweigh softer sales and margin pressure.

  • Analysts are still pointing to mixed momentum: softer North America sales and cost pressure are weighing on the near-term setup, even as investors watch for benefits from ongoing portfolio cleanup and efficiency efforts.
  • The stock is being framed around a broader improvement story, with analysts focusing on whether divestitures and cost synergies can offset weak category trends and input-cost uncertainty.
  • Recent analyst views remain mostly cautious, which makes any upside case depend less on a single catalyst and more on evidence that margin discipline and business transformation are starting to show through.
Sentiment:
⚖️Neutral

Investment Analysis

Pros

  • Colgate-Palmolive's revenue increased by over 3% in 2024 to $20.1 billion, showing steady top-line growth.
  • The company has a strong dividend yield of approximately 2.7%, providing consistent income to investors.
  • Colgate-Palmolive benefits from a diversified product portfolio spanning oral care, personal care, home care, and pet nutrition.

Considerations

  • The stock trades at a relatively high price-to-earnings ratio around 21.5, which may indicate overvaluation versus peers.
  • Colgate-Palmolive has a higher debt-to-equity ratio that could imply greater financial leverage risks.
  • The company's stock price has shown limited appreciation over the past year, suggesting growth limitations in current market conditions.

Pros

  • Kimberly-Clark is ranked highly on fundamental stock indicators, reflecting strong financial health and operational performance.
  • The company has moderate correlation with Colgate-Palmolive, offering potential portfolio diversification benefits.
  • Kimberly-Clark maintains a solid market capitalization near $44 billion, supporting its stable industry position.

Considerations

  • Kimberly-Clark’s year-to-date and annual stock performance have been lower compared to Colgate-Palmolive, indicating weaker recent momentum.
  • The stock shows moderate beta and volatility, which may lead to higher risk than more defensive consumer staple peers.
  • Limited recent growth catalysts have constrained Kimberly-Clark’s ability to outpace competitors in consumer goods.

Colgate-Palmolive (CL) Next Earnings Date

Colgate-Palmolive (CL) is expected to report next on July 31, 2026, with some sources listing August 7, 2026 as an alternative estimate. The upcoming release should cover Q2 2026 results. The most commonly cited schedule points to a late-July announcement before the market opens.

Kimberly-Clark (KMB) Next Earnings Date

Kimberly-Clark’s next earnings release is typically expected in late July to early August 2026, with current estimates clustering around July 28, 2026 to August 7, 2026. The report will cover Q2 2026 results, based on the company’s quarterly reporting cycle following its Q1 2026 release in late April. If the company has not formally confirmed a date, the most defensible expectation is an announcement in the final week of July or first week of August.

Buy CL or KMB in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions

CL
CL$93.35
vs
KMB
KMB$113.04
Buy CL